Zydus Lifesciences has launched Zyrifa, a biosimilar of Denosumab 120 mg SC, aimed at protecting bone health in cancer patients. This therapy reduces and delays Skeletal Related Events (SREs) in patients with solid tumors and multiple myeloma. Priced at Rs 12,495, Zyrifa aims to improve access to critical care medications for patients with bone metastases resulting from various cancers.
Zydus Launches Zyrifa
Zydus Lifesciences Ltd. announced the launch of Zyrifa, a biosimilar of Denosumab, on December 10, 2025. This launch aims to provide a more accessible treatment option for patients with bone metastases across various cancers.
Therapeutic Impact
Denosumab is a monoclonal antibody used for treating osteoporosis and preventing skeletal complications in cancer patients. Zyrifa will treat patients with bone metastases resulting from breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumors. The drug is priced at Rs 12,495.
Addressing Bone Metastases
Bone metastases can significantly impact a patient’s quality of life, causing pain, fractures, and reduced mobility. This condition commonly affects the spine, pelvis, and ribs. Zyrifa aims to improve affordability and access to medication for cancer patients needing critical care.
Management Commentary
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated that the goal of Denosumab 120 mg SC is to bring accessibility and affordability of medication to cancer patients needing critical care. It supports patients in retaining mobility during their fight against cancer.
Prevalence of Bone Involvement
Studies show high bone involvement rates in advanced diseases. In advanced breast or prostate cancer, bone involvement affects 50-70% of patients, while 15-40% of lung, kidney, thyroid, and melanoma cases develop skeletal metastases over time.
Biosimilar Portfolio
Zydus Lifesciences Limited has been expanding its range of biosimilars to treat various cancers, ranging from breast to prostate cancer, and has partnered with diagnostic companies.
Source: BSE
